CORAL GABLES, Fla., Aug. 25 /PRNewswire/ -- Stiefel Laboratories, the world's largest independent dermatology company, today announced that its European affiliate, Stiefel Laboratories (Ireland) Ltd., has signed an agreement to license the company's Sebiprox(R) dandruff shampoo to Grupo Ferrer International S.A. Sold by Stiefel under various brand names in Spain, France, Germany, Italy and Morocco as a treatment for dandruff and other forms of seborrheic dermatitis of the scalp, Sebiprox is the only anti-fungal dandruff shampoo that is reimbursable under most major insurance plans in Spain. The product, whose active ingredient is ciclopirox olamine, will be manufactured and supplied to Ferrer by Stiefel's manufacturing facility in Ireland. Ferrer will re-brand and sell the shampoo as part of its popular Ciclochem(R) line of anti-fungal skin and hair care products. Stiefel will continue to market the product to its core dermatologist customers under the Sebiprox name in Spain and throughout its other territories. The agreement, which covers an initial, renewable multi-year period and extends throughout all of Spain, opens the door for Ferrer to expand the distribution of Sebiprox beyond dermatologists to general practitioners and other medical professionals. According to Stiefel's Chairman, CEO & President, Charles W. Stiefel, "We are very excited to further our relationship with Ferrer and are confident that this agreement will prove to be beneficial not only for both companies, but also for those who suffer from dandruff and seborrheic dermatitis. This agreement exemplifies Stiefel's desire to partner with other companies in order to expand our coverage and bring our innovative products to those patients who need them." Ciclopirox olamine is a broad spectrum anti-fungal and anti-inflammatory agent used to treat a variety of fungus and yeast skin infections, including seborrheic dermatitis of the scalp. Seborrheic dermatitis is believed to be caused by a reaction to yeast organisms belonging to the Malassezia species. Seborrheic dermatitis is a very common condition that causes scaling and sometimes a red itchy rash of the scalp, eyebrows, face and/or chest. The condition may appear gradually or suddenly at any age, usually after puberty, and can last for many years, often getting better or worse without any apparent reason. Although there is no permanent cure for the disease, it is usually controlled by one or more treatments that include topical agents and/or therapeutic shampoos. Stiefel actively pursues acquisition opportunities and strategic alliances worldwide and welcomes collaborative ventures typified by the agreement announced today. In addition to license agreements and acquisitions, Stiefel generates new products and technologies through its world-renowned research and development group, which operates out of facilities on three continents, including the southern hemisphere's largest dermatological research facility located near Sao Paulo, Brazil. About Stiefel Laboratories, Inc. Founded in 1847, Stiefel Laboratories is the world's largest independent pharmaceutical company specialized in dermatology. Its wholly owned global network is comprised of more than 30 subsidiaries, including manufacturing plants in six countries and R&D facilities on three continents. Stiefel supplements its R&D by aggressively seeking acquisitions of dermatological product lines and companies around the world. To learn more about Stiefel, visit http://www.stiefel.com.
SOURCE Stiefel Laboratories, Inc.